Ocata Therapeutics Inc fka OCAT

[Dragon Lady]

LOL quote, "And this is where we find ourself now.
EVERYTHING before the February Up List is
irrelevant. "

What?? Not according to ALL of stock market history and ALL easily available stock market research, especially regarding literal PENNY STOCKS.

By ALL historic norms- a company who's common shares have LOST a literal 98% PLUS of their value, while literally being diluted out to 3 BILLION plus shares and down to a literal 5 CENTS a share- by all commonly available stock market research, that company has LITTLE chance to survive or ever recover as a common stock, almost none. The odds are stacked highly against it (See the SEC site or any numerous stock market research sites that track the history and performance of company's who's shares become literal "penny", as in 5 CENTS a share, stock).

And NO, a R/S (reverse split) smoke n mirrors trick does not erase that PAST and highly relevant historic, failed performance of the stock and company IMO. Not even close. (nor does a name change and "new" website and a logo change).

Everything from the instant they went public via the poor man's reverse merger- STRAIGHT to the OTC markets using the TWO MOON'S KACHINA DOLL COMPANY to get there- all of it, is highly relevant to who this company still is today.

Just read any of their SEC filings like the recent 10-K. Their legacy issues are all there, including the enormous money pit of over $350 MILLION in sunk, lost capital. Never once returning so much as ONE CENT of ROI to investors. Highly relevant.

How relevant- well here's a few "statements" about it from their most recent SEC filed 10-K:

http://www.sec.gov/Archives/edgar/data/1140098/000101968715000981/ocata_10k-123114.htm

PAGE 46 (there own CPA firm, licensed and fiduciary bound auditors speaking)

"We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Ocata Therapeutics, Inc. and Subsidiary as of December 31, 2014, and the related consolidated statements of operations, stockholders' deficit, and cash flows for the year then ended and our report dated March 16, 2015 expressed an unqualified opinion thereon and included an emphasis of a matter paragraph relating to an uncertainty as to the Company’s ability to continue as a going concern.

/s/ BDO USA, LLP
Boston, Massachusetts
March 16, 2015
"

And PAGE 43:

"We cannot assure you that public or private financing or grants will be available on acceptable terms, if at all. Several factors will affect our ability to raise additional funding, including, but not limited to, the volatility of our common stock and the broader public equity market. If we are unable to raise additional funds, we will be forced to either scale back our business efforts or curtail our business activities entirely. As of December 31, 2014, the Company has an accumulated deficit of $349.1 million, recurring losses from operations, and negative working capital which raise substantial doubt about the ability of the Company to continue as a going concern. Furthermore, an emphasis of matter paragraph related to an uncertainty as to the Company’s ability to continue as a going concern has been included in the auditor’s opinion."

It's all relevant IMO. Else, they wouldn't go out of their way to publish it in their own, Sr mgt duly signed, SEC filed 10-K statement.

Lanza quoted in a local MA newspaper:

http://www.telegram.com/article/20141014/NEWS/310149525&Template=printart

""We treated the last UK patients last month, and they also have not seen any safety issues related to the transplanted tissues themselves, either," Dr. Lanza said.

Advanced Cell now hopes to launch a 100-patient, phase 2 study in Stargardt's patients by the end of the year, according to Dr. Lanza.

A second, smaller phase 2 study in patients with age-related macular degeneration would follow, he said. Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said. "

Well, the END OF THE YEAR has come and gone and that trial has NOT started. It's almost mid 2015 now.